Freeline scores $80m Series C

UK-based Freeline, a developer of curative gene therapies for chronic systemic diseases, has raised $80 million in Series C funding.

UK-based Freeline, a developer of curative gene therapies for chronic systemic diseases, has raised $80 million in Series C funding. Novo Holdings A/S, Eventide Asset Management and Wellington Management Company led the round with participation from Cowen Healthcare Investments, Acorn Bioventures and Ample Plus Fund.

Source: Press Release